Can antiarrhythmic drugs save lives in patients with congestive heart failure?
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Can antiarrhythmic drugs save lives in patients with congestive heart failure? / Brendorp, Bente; Pedersen, Ole Dyg; Elming, Hanne; Køber, Lars; Torp-Pedersen, Christian.
I: Expert Review of Cardiovascular Therapy, Bind 1, Nr. 2, 2003, s. 191-202.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Can antiarrhythmic drugs save lives in patients with congestive heart failure?
AU - Brendorp, Bente
AU - Pedersen, Ole Dyg
AU - Elming, Hanne
AU - Køber, Lars
AU - Torp-Pedersen, Christian
N1 - Keywords: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Clinical Trials as Topic; Heart Failure; Humans; Risk Factors; Ventricular Dysfunction, Left
PY - 2003
Y1 - 2003
N2 - Although arrhythmic death is a common cause of death in patients with congestive heart failure (CHF), numerous trials involving prophylactic antiarrhythmic drug treatment have yielded few gains. To date, only beta-blockers have shown a distinct mortality-reducing effect and despite the antiarrythmic effect of gamma-blockers, results point towards causes other than the antiarrhythmic effect in obtaining this beneficial effect. Atrial fibrillation is an often-encountered arrhythmia in patients with CHF and recent trials have cast doubt on the present treatment strategy of persistently striving to obtain sinus rhythm. This paper outlines the results of the large clinical trials dealing with antiarrhythmic drug treatment in CHF patients with or without atrial fibrillation and certain subgroup analysis and future treatment possibilities are discussed.
AB - Although arrhythmic death is a common cause of death in patients with congestive heart failure (CHF), numerous trials involving prophylactic antiarrhythmic drug treatment have yielded few gains. To date, only beta-blockers have shown a distinct mortality-reducing effect and despite the antiarrythmic effect of gamma-blockers, results point towards causes other than the antiarrhythmic effect in obtaining this beneficial effect. Atrial fibrillation is an often-encountered arrhythmia in patients with CHF and recent trials have cast doubt on the present treatment strategy of persistently striving to obtain sinus rhythm. This paper outlines the results of the large clinical trials dealing with antiarrhythmic drug treatment in CHF patients with or without atrial fibrillation and certain subgroup analysis and future treatment possibilities are discussed.
U2 - 10.1586/14779072.1.2.191
DO - 10.1586/14779072.1.2.191
M3 - Journal article
C2 - 15030280
VL - 1
SP - 191
EP - 202
JO - Expert Review of Cardiovascular Therapy
JF - Expert Review of Cardiovascular Therapy
SN - 1477-9072
IS - 2
ER -
ID: 17397163